On June 23, 2009, in a speech before the Center for American Progress in Washington, D.C., Federal Trade Commission (FTC) Chairman Jon Leibvowitz reported that internal FTC analysis projects that stopping collusive “pay-for-delay” settlements between brand and generic pharmaceutical firms would save consumers $3.5 billion a year and also reap significant savings for the federal government. Chairman Leibvowitz urged Congress to pass pending legislation to ban or restrict such anticompetitive patent settlements, whereby manufacturers of brand-name drugs pay potential generic competitors to stay out of the market, as a way to control prescription drug costs, restore the benefits of generic competition, and help pay for health care reform. FTC News Release.
For more information on this and related topics, consult the CCHFDA Food, Drug and Cosmetic Law Reporter.
Visit our News Library to read more news stories.
Food, Drug and Cosmetics Law Reporter
Everything you need to know about Food and Drug Regulations.Full-text source covering federal and state laws and regulations and court decisions that govern the safety, effectiveness, purity, packaging and labeling of food, drugs and cosmetics. Learn More » |
Medical Devices ReporterAccess the full text plus expert analysis of all laws and regulations governing the classification, approval, manufacture, and marketing of all medical diagnostic, and radiological devices. Learn More »
|
